ExoTRAK: The Future of Brain Injury Intelligence
Blood-based exosome analysis delivering objective, actionable insights for concussion and traumatic brain injury assessment, monitoring, and recovery.
Request Access
The Challenge in Neurodiagnostics Today
Subjective Assessment
Current concussion evaluation relies heavily on symptom reporting and clinical observation. Athletes may underreport symptoms to return to play faster. Cognitive testing varies widely in sensitivity and specificity.
This creates dangerous gaps in clinical decision-making, particularly in time-sensitive scenarios where objective data is critical for patient safety and long-term neurological outcomes.
Limited Biomarker Access
Traditional neuroimaging captures structural damage but often misses functional injury at the cellular level. Blood-based biomarkers like S100B and GFAP provide limited temporal windows and lack specificity for repeat injury monitoring.
The absence of longitudinal tracking tools leaves clinicians without clear recovery trajectories, making return-to-activity decisions inherently uncertain and potentially risky.
Introducing ExoTRAK: Objective Brain Injury Intelligence
ExoTRAK leverages advanced exosome isolation and neuro-specific biomarker profiling to provide clinicians with precise, repeatable insights into brain injury status and recovery progression.
Blood-Based
Minimally invasive sample collection compatible with standard clinical workflows and point-of-care settings
Objective Data
Quantitative biomarker profiles that remove subjectivity from injury assessment and recovery decisions
Longitudinal Tracking
Serial monitoring capability enabling true recovery trajectory analysis and personalized return protocols
How ExoTRAK Works
The ExoTRAK platform transforms a simple blood draw into actionable neurological intelligence through a streamlined, clinically validated process designed for real-world medical environments.
01
Blood Collection
Standard venipuncture using compatible collection tubes. Samples remain stable for processing within established protocols, enabling flexible logistics for diverse clinical settings.
02
Exosome Isolation
Proprietary separation technology captures brain-derived exosomes from plasma with high purity and yield, isolating the specific nanovesicles that carry neurological signals.
03
Biomarker Analysis
Multiplex profiling of neuro-specific protein and RNA cargo within isolated exosomes, measuring markers directly linked to injury severity and recovery status.
04
Clinical Reporting
Intuitive dashboard presenting quantitative results, trend analysis, and decision support tools tailored for rapid clinical interpretation and patient counseling.
Why Exosomes Provide Superior Neurological Insight
Exosomes are nanoscale extracellular vesicles secreted by cells throughout the body, including neurons and glial cells in the central nervous system. These biological messengers carry proteins, nucleic acids, and lipids that reflect the physiological state of their cells of origin.
Brain-derived exosomes cross the blood-brain barrier, providing a unique molecular window into neurological processes that traditional blood markers cannot access. Their cargo remains protected from degradation, enabling detection of injury-specific signatures hours to days after impact.
Unlike free-floating proteins that rapidly clear from circulation, exosome-bound biomarkers persist longer and demonstrate greater specificity for neuronal damage, making them ideal for both acute assessment and extended recovery monitoring.
Clinical Applications Across the Care Continuum
Sports-Related Concussion
Objective data supporting return-to-play decisions, reducing reliance on symptom concealment and enabling safer athlete management protocols.
Military & Blast Injury
Rapid triage and longitudinal tracking for service members exposed to explosive forces or repeated subconcussive impacts during training and deployment.
Emergency & Acute Care
Enhanced triage and prognostic information in emergency departments managing motor vehicle accidents, falls, and other traumatic presentations.
Recovery Monitoring
Serial testing to track healing progression, identify persistent dysfunction, and optimize rehabilitation strategies based on objective molecular evidence.
What Sets ExoTRAK Apart
Objectivity Over Subjectivity
ExoTRAK eliminates dependence on patient-reported symptoms and observer-dependent cognitive testing. Quantitative biomarker profiles provide reproducible, unbiased data that standardizes assessment across providers and settings.
Scalable Blood-Based Platform
Compatible with existing phlebotomy infrastructure and clinical laboratory workflows. No specialized imaging equipment or lengthy neuropsychological batteries required, enabling deployment across diverse care environments from sidelines to hospitals.
Longitudinal Intelligence
Designed for serial monitoring from injury through full recovery. Baseline, acute, and follow-up testing creates personalized recovery curves that inform individualized return-to-activity timelines and detect incomplete healing.
Neuro-Specific Precision
Focused biomarker panel targeting brain-derived exosomes and their neurological cargo. Greater specificity than general inflammatory or structural markers, reducing false positives from systemic injury or other confounding conditions.
Built on Rigorous Scientific Foundation
ExoTRAK is powered by translational research originating from NanoSomiX, a leader in exosome-based biomarker discovery and validation. The platform leverages years of foundational work characterizing brain-derived extracellular vesicles and their molecular signatures in neurological injury and disease.
Our biomarker panels have undergone extensive analytical validation to establish sensitivity, specificity, and reproducibility across diverse patient populations. Ongoing clinical studies continue to expand the evidence base supporting ExoTRAK's utility in concussion and TBI management.
The technology integrates proprietary isolation methods, advanced molecular profiling, and bioinformatics algorithms trained on neurotrauma datasets. This multi-layered approach ensures that results reflect true neurobiological status rather than technical artifacts or non-specific signals.
ExoTRAK by the Numbers
48hrs
Sample to Analysis
Rapid turnaround from blood draw to exosome isolation initiation
3+
Biomarkers Profiled
Comprehensive molecular signature capturing multiple injury pathways
95%
Specificity
Accurately distinguishes true brain injury from systemic confounders
Meet the ExoTRAK Team
Masato Mitsuhashi
Dave Cohen
Bill Liatsis
John Osth
Dennis Van Epps
Scientific Publications
Acute Brain Injury Research:
1. Edwardson MA, Mitsuhashi M, Van Epps D. "Elevation of astrocyte-derived extracellular vesicles over the first month post-stroke in humans." Scientific Reports (2024) 14:5272. https://doi.org/10.1038/s41598-024-55983-w
2. Hotta N, Tadokoro T, Henry J, et al. "Monitoring of Post-Brain Injuries By Measuring Plasma Levels of Neuron-Derived Extracellular Vesicles." Biomarker Insights. 2022;17. https://doi.org/1177/11772719221128145
3. Kawata K, Mitsuhashi M, Aldret R. "A preliminary report on brain-derived extracellular vesicle as novel blood biomarkers for sport-related concussions." Front. Neurol., 12 April 2018. https://doi.org/10.3389/fneur.2018.00239
Additional publications spanning Alzheimer's disease, Parkinson's disease, ALS, and other neurological conditions demonstrate the broader platform capabilities. Link to full publication list at: https://www.nanosomix.com/publications